#USA #New York #Securities Law #Faruqi & Faruqi #Replimune

Faruqi & Faruqi's Investigation into Replimune Group Inc.

Faruqi & Faruqi, LLP, a prominent national securities law firm, recently announced its investigation regarding potential claims against Replimune Group, Inc. This investigation comes in light of a class action lawsuit that has been filed against the company, along with a critical deadline for investors.

The Class Action Lawsuit

The class action lawsuit alleges that Replimune and its executives breached federal securities laws. Specifically, the complaint states that the defendants made misleading statements and failed to disclose important information regarding the IGNYTE clinical trial results. This led to an inflated perception of Replimune's business prospects.

On July 22, 2025, Replimune communicated that it received a Complete Response Letter from the FDA regarding its Biologics License Application for RP1, a treatment designed for advanced melanoma. This letter indicated that significant concerns were raised about the adequacy and control of the IGNYTE trial, ultimately leading to the FDA's inability to approve the application. Following this announcement, Replimune's stock price plummeted by over 73%, causing substantial losses for investors.

Deadline for Lead Plaintiff

Faruqi & Faruqi urges all investors who sustained losses while purchasing or acquiring Replimune securities between November 22, 2024, and July 21, 2025, to consider their legal options. The deadline to apply for lead plaintiff status in this class action is set for September 22, 2025. Investors seeking to represent the class or those looking for more information can reach out directly to Faruqi & Faruqi senior partner James (Josh) Wilson. He can be contacted at 877-247-4292 or 212-983-9330 (Ext. 1310).

Implications for Investors

This class action not only aims to seek restitution for impacted investors but also serves as a reminder of the importance of transparency in corporate communications. Investors are encouraged to remain vigilant and informed about company disclosures and the implications of such information on their investment decisions. The outcome of this lawsuit could have significant repercussions not only for Replimune but also for investors and stakeholders involved.

Additionally, Faruqi & Faruqi welcomes any information regarding Replimune’s conduct from individuals including whistleblowers, former employees, or shareholders, as this may further bolster the case against the company.

In closing, this class action is a critical opportunity for investors to pursue potential recovery from the financial damages they have incurred due to alleged misleading statements by Replimune’s executives. Those who believe they may qualify should act promptly given the impending deadline.

For continued updates on the Replimune case, investors are encouraged to visit the firm's website or follow them on social media platforms such as LinkedIn, Facebook, and X.